Adaptimmune to acquire Boston-area cell therapy company TCR² Therapeutics
March 06, 2023 at 11:58 AM EST
The union will extend the cash runway of Adaptimmune into 2026.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |